1.0M XNAS Volume
XNAS 03 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John J. Alam | Director, CEO & President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Sylvie Gregoire | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Kelly Blackburn | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | CFO & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | CFO & GC | Purchase of securities on an exchange or from another person at price $ 18.16 per share. | 27 Aug 2024 | 1,000 | 1,267 (0%) | 0% | 18.2 | 18,160 | Common Stock |
| John J. Alam | Director, CEO & President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Joshua S. Boger | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Jane H. Hollingsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Sylvie Gregoire | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Frank Zavrl | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Marwan Noel Sabbagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Boger S. Joshua | Director, Ten Percent Owner | 26 Feb 2024 | 495,995 | 840,487 (2%) | 1% | - | Common Stock | ||
| S. Boger Joshua | Director, Ten Percent Owner | 26 Feb 2024 | 495,995 | 0 | - | - | Pre-Funded Common Stock Purchase Warrant | ||
| S. Boger Joshua | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Feb 2024 | 36 | 840,451 (2%) | 0% | - | Common Stock | |
| Joshua Boger S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Elder R. William | GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Kelly Blackburn | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| John J. Alam | Director, CEO & President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 35,500 | 35,500 | - | - | Stock Option (Right to Buy) | |
| Joseph Cobuzzi Robert | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 55,721 | 55,721 | - | - | Stock Option (Right to Buy) | |
| John William Tanner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Gregoire Sylvie | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 35,500 | 35,500 | - | - | Stock Option (Right to Buy) | |
| Diana Lanchoney | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Jun 2023 | 85 | 294 (0%) | 0% | - | Common Stock | |
| Diana Lanchoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 232 | 928 | - | - | Restricted Stock Unit | |
| Diana Lanchoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 232 | 379 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 183 | 183 | - | - | Restricted Stock Unit | |
| Jane H. Hollingsworth | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 May 2023 | 68 | 1,231 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 183 | 1,299 (0%) | 0% | - | Common Stock | |
| Diana Lanchoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 232 | 232 (0%) | 0% | - | Common Stock | |
| Diana Lanchoney | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Mar 2023 | 85 | 147 (0%) | 0% | - | Common Stock | |
| Diana Lanchoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 232 | 1,160 | - | - | Restricted Stock Unit | |
| Jane H. Hollingsworth | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2023 | 68 | 1,116 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 183 | 366 | - | - | Restricted Stock Unit | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 183 | 1,184 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 327 | 0 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jan 2023 | 121 | 1,616 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 327 | 1,737 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 183 | 1,069 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 183 | 549 | - | - | Restricted Stock Unit | |
| Jane H. Hollingsworth | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Nov 2022 | 68 | 1,001 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 327 | 1,531 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 327 | 327 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Oct 2022 | 121 | 1,410 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2022 | 121 | 1,204 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 327 | 654 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 327 | 1,325 (0%) | 0% | - | Common Stock | |
| Raven Jaeger | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 8,000 | 8,000 | - | - | Stock Option (Right to Buy) | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 183 | 838 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 May 2022 | 67 | 771 (0%) | 0% | - | Common Stock | |
| Jane H. Hollingsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 183 | 915 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 May 2022 | 121 | 998 (0%) | 0% | - | Common Sock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 327 | 1,119 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 327 | 981 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | 18 Apr 2022 | 100 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Robert Joseph Cobuzzi | Director, President & CEO | 18 Apr 2022 | 100 | 792 (0%) | 0% | 25 | 2,500 | Common Stock | |
| William R. Elder | GC & Secretary | 18 Apr 2022 | 100 | 0 | - | - | Series C Convertible Preferred Stock | ||
| William R. Elder | GC & Secretary | 18 Apr 2022 | 100 | 400 (0%) | 0% | 25 | 2,500 | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Mar 2022 | 5,000 | 5,000 | - | - | Series C Convertible Preferred Stock | |
| William R. Elder | GC & Secretary | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Mar 2022 | 5,000 | 5,000 | - | - | Series C Convertible Preferred Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jan 2022 | 6,049 | 34,602 (0%) | 0% | - | Common Stock | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 16,350 | 65,400 | - | - | Restricted Stock Unit | |
| Robert Joseph Cobuzzi | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 16,350 | 40,651 (0%) | 0% | - | Common Stock | |
| William K. Hornung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 305,743 | 305,743 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 764,357 | 764,357 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 305,743 | 305,743 | - | - | Stock Option (Right to Buy) | |
| Christopher D. Galloway | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 305,743 | 305,743 | - | - | Stock Option (Right to Buy) | |
| William Hornung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 80,069 | 80,069 | - | - | Stock Option (Right to Buy) | |
| William Hornung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 122,771 | 122,771 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 53,713 | 53,713 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 161,139 | 161,139 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 62,522 | 62,522 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 87,684 | 87,684 | - | - | Stock Option (Right to Buy) | |
| Christopher D. Galloway | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 27,180 | 27,180 | - | - | Stock Option (Right to Buy) | |
| Christopher D. Galloway | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 81,537 | 81,537 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | GC & Secretary | Purchase of securities on an exchange or from another person at price $ 0.63 per share. | 16 Nov 2020 | 5,000 | 15,000 (0%) | 0% | 0.6 | 3,150 | Common Stock |
| William R. Elder | GC & Secretary | Purchase of securities on an exchange or from another person at price $ 0.67 per share. | 16 Nov 2020 | 10,000 | 10,000 (0%) | 0% | 0.7 | 6,700 | Common Stock |
| Christopher D. Galloway | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| William R. Elder | GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2020 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | |
| Jane H. Hollingsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 54,900 | 54,900 | - | - | Restricted Stock Unit | |
| Jane H. Hollingsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 67,400 | 67,400 | - | - | Stock Option (Right to Buy) | |
| Alan G. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 61,300 | 61,300 | - | - | Stock Option (Right to Buy) | |
| Mark T. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 61,300 | 61,300 | - | - | Stock Option (Right to Buy) | |
| Robert W. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 61,300 | 61,300 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 61,300 | 61,300 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Byrne | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2020 | 118,600 | 118,600 | - | - | Stock Option (Right to Buy) | |
| Robert Joseph Cobuzzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2020 | 98,100 | 98,100 | - | - | Restricted Stock Unit | |
| David G. Kalergis | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 262,900 | 262,900 | - | - | Stock Option (Right to Buy) | |
| William Hornung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 52,600 | 52,600 | - | - | Stock Option (Right to Buy) | |
| John L. Gainer | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 239,400 | 239,400 | - | - | Stock Option (Right to Buy) | |
| Alan G. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Mark T. Giles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Robert W. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| William Hornung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 16,334 | 16,334 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Byrne | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 2,667 | 2,667 | - | - | Stock Option (Right to Buy) | |
| Robert R. Ruffolo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Alan G. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mark T. Giles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Robert R. Ruffolo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Alan G. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Mark T. Giles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| David Kalergis | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| John Gainer | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Byrne | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Ben Shealy | Sr VP Finance & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Robert R. Ruffolo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 52,057 | 52,057 | - | - | Stock Option (Right to Buy) | |
| Alan G. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2017 | 23,900 | 23,900 | - | - | Stock Option (Right to Buy) | |
| Mark T. Giles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2017 | 23,900 | 23,900 | - | - | Stock Option (Right to Buy) | |
| Robert W. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2017 | 23,900 | 23,900 | - | - | Stock Option (Right to Buy) | |
| David Kalergis | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2017 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
| John Gainer | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2017 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Ben Shealy | Sr VP Finance & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2017 | 23,100 | 23,100 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Byrne | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2017 | 4,673 | 4,673 | - | - | Stock Option (Right to Buy) | |
| Mark Giles | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 Dec 2016 | 290,580 | 802,689 | - | - | Common Stock | |
| Mark Giles | None | Other type of transaction at price $ 0.00 per share. | 27 Dec 2016 | 290,580 | 0 | - | - | Common Stock | |
| Mark Giles | None | Other type of transaction at price $ 0.00 per share. | 14 Dec 2016 | 339,055 | 290,580 | - | - | Common Stock | |
| Mark Giles | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Dec 2016 | 512,109 | 512,109 | - | - | Common Stock | |
| Alan G. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Mark Giles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| David Kalergis | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| John Gainer | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Mark A. Weinberg | Sr. V.P.- Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2014 | 521,475 | 521,475 | - | - | Stock Option (right to buy) | |
| Phillip B. Donenberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 271,475 | 271,475 | - | - | Stock Option (right to buy) | |
| Stephen M. Simes | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 542,975 | 542,975 | - | - | Stock Option (right to buy) | |
| Sol J. Barer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 123,287 | 123,287 | - | - | Stock Option (right to buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 87,449 | 87,449 | - | - | Stock Option (right to buy) | |
| Nelson K. Stacks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 61,374 | 61,374 | - | - | Stock Option (right to buy) | |
| Timothy Boris | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 79,655 | 79,655 | - | - | Stock Option (right to buy) | |
| Yael Schwartz | Director, Exe. VP Preclinical Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 119,482 | 119,482 | - | - | Stock Option (right to buy) | |
| Rex Bright | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 61,085 | 61,085 | - | - | Stock Option (right to buy) | |
| David Sherris | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2014 | 119,482 | 119,482 | - | - | Stock Option (right to buy) | |
| Sol J. Barer | Director, Chairman of the Board, Ten Percent Owner | 06 Jun 2014 | 270,616 | 728,950 | - | - | Common Stock | ||
| Sol J. Barer | Director, Chairman of the Board, Ten Percent Owner | 06 Jun 2014 | 78,473 | 807,423 | - | - | Common Stock | ||
| Sol J. Barer | Director, Chairman of the Board, Ten Percent Owner | 06 Jun 2014 | 76,755 | 884,178 | - | - | Common Stock | ||
| Sol J. Barer | Director, Chairman of the Board, Ten Percent Owner | 06 Jun 2014 | 126,894 | 1,011,072 | - | - | Common Stock | ||
| Yael Schwartz | Director, President of Subsidiaries | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2014 | 115,193 | 115,193 | - | - | Stock Option (right to buy) | |
| Craig Abolin | VP of Research & Dev - Subsid. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2014 | 57,596 | 57,596 | - | - | Stock Option (right to buy) | |
| David Sherris | Director, CSO & President of Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2014 | 115,193 | 115,193 | - | - | Stock Option (right to buy) | |
| Phillip B. Donenberg | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2014 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Stephen M. Simes | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2014 | 50,000,000 | 50,000,000 | - | - | Stock Option (right to buy) | |
| Rex Bright | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2014 | 1,650,000 | 1,650,000 | - | - | Stock Option (right to buy) | |
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 8,125,000 | 0 | - | - | Warrants (right to buy) | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 3,571,429 | 30,238,096 | - | - | Common Stock, par value $0.001 per share | ||
| Isaac Blech | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 02 May 2013 | 18,333,334 | 18,333,334 | - | - | Common Stock, par value $0.001 per share | |
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 1,250,000 | 0 | - | - | Warrants (right to buy) | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 16,250,000 | 0 | - | - | Warrants (right to buy) | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 6,500 | 0 | - | - | Series E Preferred Stock, par value $0.001 per share | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 625,000 | 0 | - | - | Warrants (right to buy) | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 108,333,333 | 138,571,429 | - | - | Common Stock, par value $0.001 per share | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 46,428,571 | 185,000,000 | - | - | Common Stock, par value $0.001 per share | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 8,333,333 | 26,666,667 | - | - | Common Stock, par value $0.001 per share | ||
| Isaac Blech | Ten Percent Owner | 02 May 2013 | 500 | 0 | - | - | Series E Preferred Stock, par value $0.001 per share |